<p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家微波消融（MWA）技术的市场领导者，今天宣布在美国建立一个专门的制造基地。这一发展标志着 Baird Medical 从专业出口商向综合全球医疗技术企业转型的关键一步。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg"/></p>
<p>将生产基地设在北美的决定是由于公司在包括印度尼西亚和马来西亚在内的十多个国家的快速商业成功。为了支持这一国际布局，Baird Medical 与位于加利福尼亚的 MPS Medical 合作，创建一个集中生产中心。该设施旨在为 Baird Medical 的先进专有技术提供全球市场，确保其不断扩大的客户群体的最高质量标准和供应链效率。</p>
<p><strong>关于 Baird Medical</strong></p>
<p>Baird Medical 是一家前瞻性的医疗设备公司，专注于微创诊断和治疗。公司致力于外科机器人系统和创新微创外科器械的研发。我们的使命是通过精确技术和先进的诊断解决方案提升患者的治疗效果。公司将与领先的学术机构建立战略合作关系。我们的愿景超越外科辅助，旨在开发智能系统，主动指导诊断决策和预防医疗策略。作为一家获得 FDA 510(k) 认证的医疗设备公司，Baird Medical 的解决方案已在美国超过 30 家知名医院和诊所中使用，包括梅奥诊所、杜兰大学医学中心、哥伦比亚大学医学中心、加州大学旧金山分校医学中心、威尔康奈尔医学中心和乔治华盛顿大学医院。Baird Medical 在中国的甲状腺微波消融设备和耗材市场也处于领先地位。同时，公司的微创治疗产品正在全球 20 多个国家逐步扩大其商业存在。</p>
<p><strong>关于 MPS Medical</strong></p>
<p>MPS Medical, Inc.是一家私人持有的医疗设备公司，在南加州设有办公室和制造设施。自 30 年前成立以来，MPS 一直致力于提供卓越的医疗设备制造服务和高质量的诊断产品，以改善美国的医疗保健和患者结果。</p>
<p>MPS 最初作为 FDA 批准的医疗设备的制造商和供应商，现在作为美国高质量外国开发医疗技术的许可、制造和分销中心。MPS 的制造设施面积超过 30,000 平方英尺，包括一个 3,000 平方英尺的 8 级洁净室和一个 18,000 平方英尺的温控仓库。该设施同时获得 FDA 注册和 ISO 认证。MPS 已获得 ISO 13485 标准、美国 FDA 21 CFR 第 820 部分质量体系法规和 ISO 14971 医疗设备风险管理标准的认证。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含某些不是历史事实的声明，而是根据 1995 年美国私人证券诉讼改革法的安全港条款的前瞻性声明。前瞻性声明通常与未来事件或 Baird Medical 未来的财务或运营表现相关。在某些情况下，您可以通过术语如 “可能”、“可以”、“应该”、“期望”、“打算”、“可能”、“将”、“估计”、“预期”、“相信”、“预算”、“预测”、“打算”、“计划”、“潜在”、“预测” 或这些术语的否定形式或变体或类似术语来识别前瞻性声明。前瞻性声明受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与这些前瞻性声明所表达或暗示的结果有重大差异。这些前瞻性声明基于 Baird Medical 及其管理层认为合理的估计和假设，但本质上是不确定的。新的风险和不确定性可能会不时出现，无法预测所有风险和不确定性。您不应对本新闻稿中的前瞻性声明过度依赖，这些声明仅在发布之日有效，并且完全受限于此处的警示声明。Baird Medical 不承担更新这些前瞻性声明的任何义务。</p>
<p>实际结果可能因多种因素而与前瞻性声明所表达或暗示的结果有重大差异，包括但不限于：（1）Baird Medical 在中国或美国扩展业务可能不成功的风险；（2）一般经济条件的变化；（3）监管条件和发展；（4）适用法律或法规的变化；（5）对 Baird Medical 或其他人提起的待决和未来诉讼及其他法律程序的性质、成本和结果；（6）在与商业合并相关的注册声明和过渡报告中不时描述的其他风险和不确定性，包括在其中标题为 “风险因素” 的部分列出的风险，以及 ExcelFin 向 SEC 的其他文件。</p>
<p>上述因素清单并不排他。有关这些及其他风险因素的更多信息，请参阅 ExcelFin 最近向美国证券交易委员会（SEC）提交的文件，以及 Baird Medical 在与 ExcelFin 的业务合并中提交的上述注册声明。所有后续的书面和口头前瞻性声明，涉及 Baird Medical、本文所述的业务合并或其他归因于 Baird Medical 或其代表的任何人的事项，均明确受到上述警示声明的完全限制。读者被提醒不要对任何前瞻性声明过度依赖，这些声明仅在作出时有效。Baird Medical 明确声明不承担任何义务或承诺，公开发布任何前瞻性声明的更新或修订，以反映其预期的任何变化或任何基于的事件、条件或情况的变化。</p>
<p><strong>联系方式：</strong> Eric Huang，公关联络人</p>
<p>Baird Medical Investment Holdings Ltd.</p>
<p>电话：+1 (888) 508-6228</p>
<p>电子邮件：ir@bairdmed.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847018/BDMD_team.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847018/BDMD_team.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>来源 BDMD</p>

<p>Baird Medical Investment Holdings Ltd.（纳斯达克代码：BDMD）在美国建立了一个制造基地，以支持其全球扩张和未来的研发。与 MPS Medical 合作，新设施将提升 Baird 先进医疗技术的生产和供应链效率。Baird Medical 专注于微创诊断和治疗，在 20 多个国家和美国的领先医院中拥有强大的市场存在。该公司旨在开发用于诊断决策和预防医疗策略的智能系统</p>

<p>, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (&#34;Baird Medical&#34; or the &#34;Company&#34;), a market leader in Microwave Ablation (MWA) technology, today announced the establishment of a dedicated manufacturing base in the United States. This development marks a pivotal step in Baird Medical's transition from a specialized exporter to a comprehensive global medical technology enterprise.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家微波消融（MWA）技术的市场领导者，今天宣布在美国建立一个专门的制造基地。这一发展标志着 Baird Medical 从专业出口商向综合全球医疗技术企业转型的关键一步。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg" alt="" original-src="https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg"/></p>
<p>The decision to anchor production in North America is driven by the Company's rapid commercial success across over a dozen countries, including recent significant market penetrations in Indonesia and Malaysia. To support this international footprint, Baird Medical has partnered with California-based MPS Medical to create a centralized production hub. This facility is designed to supply Baird Medical's advanced proprietary technologies to global markets, ensuring the highest standards of quality and supply chain efficiency for its expanding client base.</p>
<div class="lb-trans"><p>将生产基地设在北美的决定是由于公司在包括印度尼西亚和马来西亚在内的十多个国家的快速商业成功。为了支持这一国际布局，Baird Medical 与位于加利福尼亚的 MPS Medical 合作，创建一个集中生产中心。该设施旨在为 Baird Medical 的先进专有技术提供全球市场，确保其不断扩大的客户群体的最高质量标准和供应链效率。</p>
</div><p><strong>About Baird Medical</strong></p>
<div class="lb-trans"><p><strong>关于 Baird Medical</strong></p>
</div><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p>
<div class="lb-trans"><p>Baird Medical 是一家前瞻性的医疗设备公司，专注于微创诊断和治疗。公司致力于外科机器人系统和创新微创外科器械的研发。我们的使命是通过精确技术和先进的诊断解决方案提升患者的治疗效果。公司将与领先的学术机构建立战略合作关系。我们的愿景超越外科辅助，旨在开发智能系统，主动指导诊断决策和预防医疗策略。作为一家获得 FDA 510(k) 认证的医疗设备公司，Baird Medical 的解决方案已在美国超过 30 家知名医院和诊所中使用，包括梅奥诊所、杜兰大学医学中心、哥伦比亚大学医学中心、加州大学旧金山分校医学中心、威尔康奈尔医学中心和乔治华盛顿大学医院。Baird Medical 在中国的甲状腺微波消融设备和耗材市场也处于领先地位。同时，公司的微创治疗产品正在全球 20 多个国家逐步扩大其商业存在。</p>
</div><p><strong>About MPS Medical</strong></p>
<div class="lb-trans"><p><strong>关于 MPS Medical</strong></p>
</div><p>MPS Medical, Inc. is a privately held medical device company with offices and manufacturing facilities Southern California. Since its founding 30 years ago, MPS has been committed to providing exceptional medical device manufacturing services and high-quality diagnostic products to help improve healthcare and patient outcomes throughout the United States.</p>
<div class="lb-trans"><p>MPS Medical, Inc.是一家私人持有的医疗设备公司，在南加州设有办公室和制造设施。自 30 年前成立以来，MPS 一直致力于提供卓越的医疗设备制造服务和高质量的诊断产品，以改善美国的医疗保健和患者结果。</p>
</div><p>MPS was founded as a manufacturer and supplier of FDA-approved medical devices and now serves as a U.S. hub for the licensing, manufacturing, and distribution of high-quality, foreign-developed medical technologies. MPS manufacturing facility is over 30,000 sq ft, including a 3,000 sq ft class 8 cleanroom and an 18,000 sq ft temperature-controlled warehouse. The facility is both FDA registered and ISO certified. MPS's is certified to ISO 13485 standards, US FDA 21 CFR Part 820 Quality System regulations and ISO 14971 Medical Device, Risk Management standards.</p>
<div class="lb-trans"><p>MPS 最初作为 FDA 批准的医疗设备的制造商和供应商，现在作为美国高质量外国开发医疗技术的许可、制造和分销中心。MPS 的制造设施面积超过 30,000 平方英尺，包括一个 3,000 平方英尺的 8 级洁净室和一个 18,000 平方英尺的温控仓库。该设施同时获得 FDA 注册和 ISO 认证。MPS 已获得 ISO 13485 标准、美国 FDA 21 CFR 第 820 部分质量体系法规和 ISO 14971 医疗设备风险管理标准的认证。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as &#34;may&#34;, &#34;could&#34;, &#34;should&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;might&#34;, &#34;will&#34;, &#34;estimate&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;budget&#34;, &#34;forecast&#34;, &#34;intend&#34;, &#34;plan&#34;, &#34;potential&#34;, &#34;predict&#34;, or &#34;continue&#34;, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含某些不是历史事实的声明，而是根据 1995 年美国私人证券诉讼改革法的安全港条款的前瞻性声明。前瞻性声明通常与未来事件或 Baird Medical 未来的财务或运营表现相关。在某些情况下，您可以通过术语如 “可能”、“可以”、“应该”、“期望”、“打算”、“可能”、“将”、“估计”、“预期”、“相信”、“预算”、“预测”、“打算”、“计划”、“潜在”、“预测” 或这些术语的否定形式或变体或类似术语来识别前瞻性声明。前瞻性声明受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与这些前瞻性声明所表达或暗示的结果有重大差异。这些前瞻性声明基于 Baird Medical 及其管理层认为合理的估计和假设，但本质上是不确定的。新的风险和不确定性可能会不时出现，无法预测所有风险和不确定性。您不应对本新闻稿中的前瞻性声明过度依赖，这些声明仅在发布之日有效，并且完全受限于此处的警示声明。Baird Medical 不承担更新这些前瞻性声明的任何义务。</p>
</div><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled &#34;Risk Factors&#34; therein, and in ExcelFin's other filings with the SEC.</p>
<div class="lb-trans"><p>实际结果可能因多种因素而与前瞻性声明所表达或暗示的结果有重大差异，包括但不限于：（1）Baird Medical 在中国或美国扩展业务可能不成功的风险；（2）一般经济条件的变化；（3）监管条件和发展；（4）适用法律或法规的变化；（5）对 Baird Medical 或其他人提起的待决和未来诉讼及其他法律程序的性质、成本和结果；（6）在与商业合并相关的注册声明和过渡报告中不时描述的其他风险和不确定性，包括在其中标题为 “风险因素” 的部分列出的风险，以及 ExcelFin 向 SEC 的其他文件。</p>
</div><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>
<div class="lb-trans"><p>上述因素清单并不排他。有关这些及其他风险因素的更多信息，请参阅 ExcelFin 最近向美国证券交易委员会（SEC）提交的文件，以及 Baird Medical 在与 ExcelFin 的业务合并中提交的上述注册声明。所有后续的书面和口头前瞻性声明，涉及 Baird Medical、本文所述的业务合并或其他归因于 Baird Medical 或其代表的任何人的事项，均明确受到上述警示声明的完全限制。读者被提醒不要对任何前瞻性声明过度依赖，这些声明仅在作出时有效。Baird Medical 明确声明不承担任何义务或承诺，公开发布任何前瞻性声明的更新或修订，以反映其预期的任何变化或任何基于的事件、条件或情况的变化。</p>
</div><p><strong>Contact:</strong> Eric Huang, PR Liaison</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Eric Huang，公关联络人</p>
</div><p>Baird Medical Investment Holdings Ltd.</p>
<div class="lb-trans"><p>Baird Medical Investment Holdings Ltd.</p>
</div><p>Phone: +1 (888) 508-6228</p>
<div class="lb-trans"><p>电话：+1 (888) 508-6228</p>
</div><p>Email: ir@bairdmed.com</p>
<div class="lb-trans"><p>电子邮件：ir@bairdmed.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847018/BDMD_team.jpg" alt="" original-src="https://mma.prnewswire.com/media/2847018/BDMD_team.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>SOURCE BDMD</p>
<div class="lb-trans"><p>来源 BDMD</p>
</div>

贝尔德医疗在美国建立制造基地，以加速其全球扩张和未来的研发 | BDMD 股票新闻